A proprietary algorithm can help payers identify patients at high risk of progressive chronic kidney disease.
The diagnostics company RenalytixAI and drug maker AstraZeneca have announced a collaboration to use artificial intelligence (AI) for precision medicine strategies in cardiovascular, renal, and metabolic diseases. The companies offered a joint statement on the partnership Friday.
The partnership will begin with KidneyIntelX, described in the joint announcement as “an AI-enabled in vitro diagnostic platform.” The platform uses a proprietary AI algorithm to evaluate patient data, collected from electronic health records or genetic testing, to develop a risk score that lets physicians know if the patient is at risk of declining kidney function. From this risk score, payers and health systems can make coverage decisions for patients with diabetic kidney disease.
In this new venture, AstraZeneca and RenalytixAI will work with Mount Sinai Health System to use the KidneyIntelx testing platform and software in a randomized controlled trial, which will evaluate “uptake and adherence” among patients with chronic kidney disease (CKD) and hyperkalemia who are taking new potassium-binding agents. According to the companies’ joint statement, the KidneyIntelX platform is already in use at Mount Sinai.
An estimated 37 million Americans have CKD, which can lead to renal failure and the need for dialysis. Rising rates of obesity and an aging population are both contributing to an increase in CKD, which accounts for $1 in every $5 spent by Medicare. Unfortunately, patients with early stage kidney disease often have no symptoms, which can allow renal decline to go unchecked. Other complications of CKD include anemia or hyperkalemia.
Results from the collaboration are expected in early 2021, the statement said.
“We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases, such as kidney disease, diabetes, and cardiovascular disease,” said Barbara Murphy, MD, who is chair of the Samuel Bronfman Department of Medicine, dean for Clinical Integration and Population Health Management at the Icahn School of Medicine at Mount Sinai, and a board member of RenalytixAI. “By using a more personalized approach, our initial goal is to help realize improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System.”
Goals of the partnership between RenalytixAI and AstraZeneca include:
“This collaborative approach reflects the shared vision of AstraZeneca and RenalytixAI to develop meaningful solutions to tackle significant challenges in healthcare in a holistic way,” said Tarek Rabah, vice president, AstraZeneca US Renal-Cardio. “We are committed to revolutionizing kidney care by continuing to drive innovation. An important component of our work is identifying patients with significant unmet need and providing them with more personalized interventions.”
Results from DAPA-CKD, which studied the use of the sodium glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin in CKD, are scheduled to be presented next weekend during the European Society of Cardiology Virtual Congress. AstraZeneca markets the SGLT2 inhibitor as Farxiga. Last month, the drug maker announced that DAPA-CKD had met all primary and secondary end points for patients with CKD, whether or not they had diabetes.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen